Credits Available: 4.75 AMA PRA Category 1 Credit™/ MOC Points

Description: This curriculum examines the latest advancements in antibody-drug conjugate (ADC) therapy for metastatic triple-negative breast cancer (mTNBC) and HER2-low (HER+/HER2-) breast cancer. It provides insights into mechanisms of action, emerging clinical data, and strategies for integrating ADCs into treatment regimens to improve patient outcomes. Expert-led discussions and case-based learning will support clinicians in individualizing therapy and addressing real-world challenges in ADC use.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant
Target Specialties: Oncology

Veronica Franz

Nuvance Health Breast Sugery
FNP

My name is Veronica Franz, NP. I graduated with my BSN in 2012 and was a bedside Oncology nurse until I graduated with my MSN in 2019. I have been working in the breast surgery department since, treating both benign and malignant conditions. I truly enjoy educating my peers on oncological topics.